Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

28

Revenue 2017

Ibrance

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Ibrance was produced by Pfizer.

The handover: Pfizer reshapes itself for a new era

The handover: Pfizer reshapes itself for a new era

Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class 6 inhibitor, a newer drug group which includes Novartis’ own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).

Lilly gets EMA nod for Verzenio in breast cancer

Lilly gets EMA nod for Verzenio in breast cancer The approved uses match the indications for Verzenio in the US, and take Lilly another step forward in its pursuit of CDK4/6 market leader Ibrance (palbociclib) from Pfizer - which grew ... Meanwhile, the first signs of weakness in Ibrance sales were

Pfizer names next CEO as Read retires

Pfizer names next CEO as Read retires This has been achieved thanks to 30 FDA approvals over the period, including market leading breast cancer drug Ibrance, which earned more than £3bn last year.

Biopharma's Future: Made in China

Biopharma's Future: Made in China In 2018 it has issued a flurry of approvals to new and innovative drugs such as MSD’s Keytruda and Pfizer’s Ibrance.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics